Halozyme Therapeutics Inc.

46.11-0.0900-0.19%Vol 196.56K1Y Perf 147.18%
Apr 16th, 2021 10:48 DELAYED
BID46.11 ASK46.16
Open46.49 Previous Close46.20
Pre-Market- After-Market-
 - -%  - -
Target Price
41.73 
Analyst Rating
Moderate Buy 1.71
Potential %
-9.18 
Finscreener Ranking
+     39.62
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     43.80
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     59.06
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap6.61B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
72.79 
Earnings Date
10th May 2021

Today's Price Range

45.6846.61

52W Range

18.5856.40

5 Year PE Ratio Range

-27.8050.00

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
8.02%
1 Month
4.17%
3 Months
-2.59%
6 Months
60.67%
1 Year
147.18%
3 Years
139.75%
5 Years
285.96%
10 Years
618.51%

TickerPriceChg.Chg.%
HALO46.11-0.0900-0.19
AAPL134.37-0.1300-0.10
GOOG2 292.00-4.6600-0.20
MSFT259.860.36000.14
XOM56.91-0.0700-0.12
WFC43.341.10002.60
JNJ160.790.40000.25
FB305.65-2.1700-0.70
GE13.48-0.0700-0.52
JPM153.811.64001.08
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.30
0.80
2.63
7.30
Leverage Ratio 4.30
ProfitabilityValueIndustryS&P 500US Markets
83.80
55.90
57.20
-18.20
56.72
RevenueValueIndustryS&P 500US Markets
242.24M
1.69
-2.58
8.15
Earnings HistoryEstimateReportedSurprise %
Q04 20200.560.50-10.71
Q03 20200.200.2525.00
Q02 20200.250.19-24.00
Q01 2020-0.01-0.04-300.00
Q04 2019-0.18-0.24-33.33
Q03 2019-0.12-0.17-41.67
Q02 2019-0.17-0.1041.18
Q01 20190.010.010.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.31-16.22Negative
6/2021 QR0.36-18.18Negative
12/2021 FY1.53-11.05Negative
12/2022 FY2.713.44Positive
Next Report Date10th May 2021
Estimated EPS Next Report0.31
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume196.56K
Shares Outstanding143.30M
Trades Count1.78K
Dollar Volume203.86M
Avg. Volume1.38M
Avg. Weekly Volume880.74K
Avg. Monthly Volume1.17M
Avg. Quarterly Volume1.39M

Halozyme Therapeutics Inc. (NASDAQ: HALO) stock closed at 46.2 per share at the end of the most recent trading day (a 0.54% change compared to the prior day closing price) with a volume of 887.91K shares and market capitalization of 6.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 136 people. Halozyme Therapeutics Inc. CEO is Helen I. Torley.

The one-year performance of Halozyme Therapeutics Inc. stock is 147.18%, while year-to-date (YTD) performance is 8.17%. HALO stock has a five-year performance of 285.96%. Its 52-week range is between 18.58 and 56.4, which gives HALO stock a 52-week price range ratio of 72.79%

Halozyme Therapeutics Inc. currently has a PE ratio of 46.40, a price-to-book (PB) ratio of 40.04, a price-to-sale (PS) ratio of 25.41, a price to cashflow ratio of 107.70, a PEG ratio of 2.32, a ROA of 21.59%, a ROC of 10.85% and a ROE of 102.88%. The company’s profit margin is 56.72%, its EBITDA margin is 57.20%, and its revenue ttm is $242.24 Million , which makes it $1.69 revenue per share.

Of the last four earnings reports from Halozyme Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Halozyme Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Halozyme Therapeutics Inc. is Moderate Buy (1.71), with a target price of $41.73, which is -9.18% compared to the current price. The earnings rating for Halozyme Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Halozyme Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Halozyme Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 2.58, CCI20 : 225.47, Chaikin Money Flow : 0.01, MACD : -0.92, Money Flow Index : 83.57, ROC : 14.22, RSI : 50.39, STOCH (14,3) : 86.59, STOCH RSI : 1.00, UO : 56.86, Williams %R : -13.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Halozyme Therapeutics Inc. in the last 12-months were: Connie L. Matsui (Sold 32 000 shares of value $865 792 ), Elaine D. Sun (Option Excercise at a value of $0), Helen I. Torley (Option Excercise at a value of $0), Helen I. Torley (Sold 200 000 shares of value $8 865 189 ), James M. Daly (Sold 79 037 shares of value $2 418 587 ), Jeffrey W. Henderson (Sold 24 498 shares of value $981 757 ), Kenneth J. Kelley (Sold 101 549 shares of value $4 237 715 ), Masaru Matsuda (Option Excercise at a value of $0), Michael LaBarre (Option Excercise at a value of $609 499), Michael LaBarre (Sold 140 400 shares of value $4 921 238 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (16.67 %)
Moderate Sell
1 (14.29 %)
1 (14.29 %)
1 (16.67 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.71
Moderate Buy
1.71
Moderate Buy
1.83

Halozyme Therapeutics Inc.

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

CEO: Helen I. Torley

Telephone: +1 858 794-8889

Address: 11388 Sorrento Valley Road, San Diego 92121, CA, US

Number of employees: 136

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

61%39%

Bearish Bullish

52%48%

News

Stocktwits